Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Medicxi/Activity

Medicxi Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Exit

Portfolio company Centessa Pharmaceuticals agreed to be acquired by Eli Lilly for approximately $7.8 billion.

Centessa Pharmaceuticals

Centessa Pharmaceuticals Medicxi

investor.lilly.comMAR 31, 2026

Medicxi | Activity | F4

cnbc.com

MAR 31, 2026

Exit

Portfolio company RAPT Therapeutics agreed to be acquired by GSK for approximately $1.9-2.2 billion.

RAPT Therapeutics

RAPT TherapeuticsMedicxi

investors.rapt.comJAN 20, 2026

JAN 20, 2026

Team Change

Promoted Shyam Masrani to Partner alongside the close of Fund V.

Shyam Masrani promoted to Partner

medicxi.comNOV 14, 2025

NOV 14, 2025

New Fund

Closed Medicxi V, a €500 million fund, bringing total capital raised across six funds to over €2.0 billion.

Medicxi V (€500M)

medicxi.comNOV 14, 2025

NOV 14, 2025

Exit

Portfolio company Vicebio agreed to be acquired by Sanofi for up to $1.6 billion.

Vicebio

VicebioMedicxi

prnewswire.comJUL 22, 2025

JUL 22, 2025

Investment

Invested $40 million in D3 Bio to advance its oncology pipeline.

D3 Bio

medicxi.comAPR 8, 2024

APR 8, 2024